Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05262400 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

A Phase 1 study of Breast Cancer and Solid Tumors, sponsored by Pfizer.

Active
Registry status
Phase 1
Development phase
192
Enrollment target
20
Study locations

NCT05262400 is a Phase 1 study of Breast Cancer and Solid Tumors that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 192 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05262400, a Phase 1 study of Breast Cancer and Solid Tumors, is active but no longer recruiting, sponsored by Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
192 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: * Have been diagnosed with Breast Cancer (BC) of either types: * Have HR+, HER2- BC * Refractory HR-positive/HER2-positive BC * Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount of study medicines that can be safety given to people. All participants in this study will receive PF-07220060 with PF-07104091 by mouth. We will compare participant experiences to help us determine if PF-07220060 with PF-07104091 is safe and effective. Participants will take part in this study for about 2 years. During this time, they will receive the study medicine, an x-ray imaging, and will be observed for safety and effects of the study medicines.

Conditions Studied

Breast Cancer Solid Tumors

Interventions

  • DRUG PF-07220060 + PF-07104091 combination dose escalation

Study Locations (20)

California

  • Administrative Address: UCLA Hematology/Oncology - Los Angeles
  • Ronald Reagan UCLA Medical Center - Los Angeles
  • UCLA Hematology/Oncology - Los Angeles
  • UCLA Hematology / Oncology-Parkside - Santa Monica
  • UCLA Hematology/Oncology-Santa Monica - Santa Monica

Other

  • Centro Oncologico Korben - Buenos Aires
  • Clínica Universitaria Reina Fabiola - Córdoba
  • Fundación CORI para la Investigación y Prevención del Cáncer - La Rioja

Rio Grande do Sul

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia - Ijuí
  • Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa - Porto Alegre
  • Centro de Pesquisa Clínica - Área Administrativa - Porto Alegre

Texas

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center - Dallas
  • The University of Texas MD Anderson Cancer Center - Houston

Washington

  • Swedish Medical Center - Seattle
  • Swedish Medical Center - Seattle

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • START Midwest - Grand Rapids

Missouri

  • Saint Luke's Cancer Institute - Kansas City

Trial Details

FieldValue
Enrollment Target 192 participants
Start Date 2022-03-14
Est. Completion 2026-08-23
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05262400

The ClinicalTrials.gov registry entry for NCT05262400 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which PF-07220060 + PF-07104091 combination dose escalation is the first listed.

NCT05262400 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Other, Rio Grande do Sul.

Frequently Asked Questions

What is clinical trial NCT05262400 about?

NCT05262400 is a clinical study titled "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: * Have been diagnosed with Br...

What is the current status of trial NCT05262400?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2022-03-14. Estimated completion is 2026-08-23.

What conditions does trial NCT05262400 study?

This clinical trial studies the following conditions: Breast Cancer, Solid Tumors.

What interventions are being tested in trial NCT05262400?

The interventions under investigation include: PF-07220060 + PF-07104091 combination dose escalation (DRUG).

Who is sponsoring clinical trial NCT05262400?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05262400 being conducted?

This trial has 20 study locations across California, Massachusetts, Michigan, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.